dc.contributor.author |
Soldevila-Verdeguer, C.
|
|
dc.contributor.author |
Segura-Sampedro, J.J.
|
|
dc.contributor.author |
Pineño-Flores, C.
|
|
dc.contributor.author |
Sanchís-Cortés, P.
|
|
dc.contributor.author |
González-Argente, X.
|
|
dc.contributor.author |
Morales-Soriano, R.
|
|
dc.date.accessioned |
2020-06-19T06:05:55Z |
|
dc.identifier.uri |
http://hdl.handle.net/11201/152954 |
|
dc.description.abstract |
[eng] Background and objectives Cytoreductive surgery with hyperthermic intraperitoneal chemotherapy (CRS-HIPEC) is an effective but complex treatment for peritoneal metastasis (PM). Our objective was to identify risk factors for postoperative morbidity and mortality following CRS-HIPEC. Methods Retrospective study of prospectively collected data of patients undergoing CRS-HIPEC for PM arises from colorectal cancer between January 2008 and December 2017. Perioperative variables were correlated with morbidity outcomes using a logistic regression model. Results Sixty-seven patients underwent CRS-HIPEC, and overall morbidity and mortality were 31.3% and 4.5% respectively. Major morbidity rate was 19.4%; 7.5% of patients were re-operated. Intraoperative blood transfusion (p = 0.01), liver resection (p < 0.01), and intestinal anastomosis (p < 0.01) were associated with a higher morbidity in univariate analysis. A multivariate analysis identified blood transfusion and liver resection as independent risk factors (OR 3.66, IC 1.13-16.54; OR 4.33, IC 1.17-11.46, respectively). Extension of visceral resection did not correlate with morbidity. Patients with lymph-node infiltration had a higher major complication rate (p = 0.01). Conclusions CRS-HIPEC is a feasible treatment for colorectal PM with an acceptable morbi-mortality rate in experienced centers. In our study, digestive anastomosis, perioperative blood transfusion, hepatic resection, and lymph-node infiltration were associated with higher morbidity rates. |
|
dc.format |
application/pdf |
|
dc.relation.isformatof |
Versió postprint del document publicat a: https://doi.org/10.1007/s12094-020-02346-2 |
|
dc.relation.ispartof |
Clinical & Translational Oncology, 2020, vol. 2020 |
|
dc.rights |
(c) Federación de Sociedades Españolas de Oncología (FESEO), 2020 |
|
dc.subject.classification |
61 - Medicina |
|
dc.subject.other |
61 - Medical sciences |
|
dc.title |
Hepatic resection and blood transfusion increase morbidity after cytoreductive surgery and HIPEC for colorectal carcinomatosis |
|
dc.type |
info:eu-repo/semantics/article |
|
dc.type |
info:eu-repo/semantics/acceptedVersion |
|
dc.date.updated |
2020-06-19T06:05:55Z |
|
dc.date.embargoEndDate |
info:eu-repo/date/embargoEnd/2026-12-31 |
|
dc.embargo |
2026-12-31 |
|
dc.subject.keywords |
Transfusión sanguínea |
|
dc.subject.keywords |
Cirugía de citorreducción + HIPEC |
|
dc.subject.keywords |
Hepatectomía |
|
dc.subject.keywords |
Carcinomatosis peritoneal |
|
dc.subject.keywords |
Morbilidad |
|
dc.rights.accessRights |
info:eu-repo/semantics/embargoedAccess |
|
dc.identifier.doi |
https://doi.org/10.1007/s12094-020-02346-2 |
|